NEW YORK (GenomeWeb News) – Theranostics Health said today it has licensed proteomic biomarker discovery technology from the National Institutes of Health that was developed by the company’s founders.
The Rockville, Md.-based company’s core technology, Reverse Phase Protein Microarray combined with Laser Capture Microdissection, was developed by company co-founders Emanuel Petricoin and Lance Liotta.
Under the agreement, Theranostics will pay NIH license issue royalties, minimum annual royalties, and benchmark and earned royalties upon successful commercialization of the technology.
Petricoin, CSO of Theranostics, said in a statement that the company's “unique signaling pathway platform allows the activity of theranostic biomarkers of interest to be quantitatively measured from microdissected patient samples.”
Theranostics Health CEO Danong Chen said the exclusive license allows the company to develop companion diagnostics to be used in treatment decision-making and monitoring.